Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 7/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2716086 | 1.00 | PTGS1 (0.39) | PTGS1CYP3A4MAPK1ESR1ESR2 | |
| SCHEMBL2716085 | 1.00 | PTGS1 (0.39) | PTGS1CYP3A4MAPK1ESR1ESR2 | |
| SCHEMBL15954206 | 1.00 | PTGS1 (0.39) | PTGS1CYP3A4MAPK1ESR1ESR2 | |
| SCHEMBL30362837 | 1.00 | PTGS1 (0.39) | PTGS1CYP3A4MAPK1ESR1ESR2 | |
| SCHEMBL30362814 | 0.88 | ESR1 (0.36) | PTGS1CYP3A4ESR1ESR2ALOX15 | |
| SCHEMBL10074001 | 0.88 | ESR1 (0.36) | PTGS1CYP3A4ESR1ESR2ALOX15 | |
| SCHEMBL15312086 | 0.88 | ESR1 (0.36) | PTGS1CYP3A4ESR1ESR2ALOX15 | |
| SCHEMBL2713088 | 0.88 | ESR1 (0.36) | PTGS1CYP3A4ESR1ESR2ALOX15 | |
| SCHEMBL2713457 | 0.88 | PTGS1 (0.41) | PTGS1CYP3A4MAPK1PTPN1CYP2D6 | |
| SCHEMBL30362778 | 0.88 | PTGS1 (0.41) | PTGS1CYP3A4MAPK1PTPN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | Aardvark Therapeutic, Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2024137472-A2 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| CN-116139125-A | Combination therapy | 梅制药公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2021252776-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210000790-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-20190142790-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20170246142-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20170246142-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-9663484-B2 | Isoflavonoid compounds and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663484-B2 | Isoflavonoid compounds and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2012061409-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | PTGS1 1926/4885CYP3A4 4003/4885MAPK1 938/4885 |
| US-20210000790-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | PTGS1 326/4885CYP3A4 2283/4885MAPK1 3060/4885 |
| US-20230233519-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL2L2 | PTGS1 1212/4885CYP3A4 4039/4885MAPK1 3494/4885 |
| US-20190142790-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | PTGS1 326/4885CYP3A4 2283/4885MAPK1 3060/4885 |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | PTGS1 326/4885CYP3A4 2283/4885MAPK1 3060/4885 |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | PTGS1 326/4885CYP3A4 2283/4885MAPK1 3060/4885 |
| US-20170246142-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | PTGS1 326/4885CYP3A4 2283/4885MAPK1 3060/4885 |
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | BAX, CASP3, API5 | PTGS1 326/4885CYP3A4 2283/4885MAPK1 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.